Abstract
“Ex vivo” regional gene therapy using lentiviral (LV) vectors to over-express bone morphogenetic protein 2 (BMP-2) is an effective way to enhance bone healing in animal models. Here, we evaluated two different “ex vivo” approaches using either “same day” rat bone marrow cells (SDRBMCs) or cultured rat bone marrow cells (C-RBMCs), both transduced with a LV based two-step transcriptional activation system overexpressing GFP (LV-TSTA-EGFP), to assess the fate of the transduced cells and the safety of this approach. The transduced cells were implanted in femoral defects of syngeneic rats. Animals were sacrificed at 4, 14, 28 and 56 days after surgery (n=5 per group). Viral copies were detectable in the defect site of SD-RBMC group and gradually declined at 8w (5 log decrease compared to 4d). In the C-RBMC animals, there was a 2-4 log decline in the viral copy numbers at 2w and 4w, but at 8w there was a relative rise (about 100 fold) in the number of the viral vectors in the defect site of 4 (out of 5) animals compared to the previous time points. For both gene transfer approaches, the pattern of tissue distribution was non-specific and no histological abnormalities were noted in either group. In summary, we demonstrated that the LV-TSTA transduced cells remain in the defect site for at least 56 days, though the numbers decreased over time. There were no consistent findings of viral copies in internal organs which is encouraging with respect to the development of this strategy for use in humans.
Keywords: Viral vector distribution, Bone repair, ex vivo gene therapy and safety.
Current Gene Therapy
Title:Biodistribution of LV-TSTA Transduced Rat Bone Marrow Cells Used for “Ex-vivo” Regional Gene Therapy for Bone Repair
Volume: 15 Issue: 5
Author(s): Farhang Alaee, Cynthia Bartholomae, Osamu Sugiyama, Mandeep S. Virk, Hicham Drissi, Qian Wu, Manfred Schmidt and Jay R. Lieberman
Affiliation:
Keywords: Viral vector distribution, Bone repair, ex vivo gene therapy and safety.
Abstract: “Ex vivo” regional gene therapy using lentiviral (LV) vectors to over-express bone morphogenetic protein 2 (BMP-2) is an effective way to enhance bone healing in animal models. Here, we evaluated two different “ex vivo” approaches using either “same day” rat bone marrow cells (SDRBMCs) or cultured rat bone marrow cells (C-RBMCs), both transduced with a LV based two-step transcriptional activation system overexpressing GFP (LV-TSTA-EGFP), to assess the fate of the transduced cells and the safety of this approach. The transduced cells were implanted in femoral defects of syngeneic rats. Animals were sacrificed at 4, 14, 28 and 56 days after surgery (n=5 per group). Viral copies were detectable in the defect site of SD-RBMC group and gradually declined at 8w (5 log decrease compared to 4d). In the C-RBMC animals, there was a 2-4 log decline in the viral copy numbers at 2w and 4w, but at 8w there was a relative rise (about 100 fold) in the number of the viral vectors in the defect site of 4 (out of 5) animals compared to the previous time points. For both gene transfer approaches, the pattern of tissue distribution was non-specific and no histological abnormalities were noted in either group. In summary, we demonstrated that the LV-TSTA transduced cells remain in the defect site for at least 56 days, though the numbers decreased over time. There were no consistent findings of viral copies in internal organs which is encouraging with respect to the development of this strategy for use in humans.
Export Options
About this article
Cite this article as:
Alaee Farhang, Bartholomae Cynthia, Sugiyama Osamu, Virk S. Mandeep, Drissi Hicham, Wu Qian, Schmidt Manfred and Lieberman R. Jay, Biodistribution of LV-TSTA Transduced Rat Bone Marrow Cells Used for “Ex-vivo” Regional Gene Therapy for Bone Repair, Current Gene Therapy 2015; 15 (5) . https://dx.doi.org/10.2174/1566523215666150812120229
DOI https://dx.doi.org/10.2174/1566523215666150812120229 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applications of Cellular Systems Biology in Breast Cancer Patient Stratification and Diagnostics
Combinatorial Chemistry & High Throughput Screening Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer
Current Cancer Drug Targets MR Diffusion-Weighted Imaging in Evaluating Immediate HIFU Treatment Response of Uterine Fibroids
Current Medical Imaging Screening for Infectious Diseases During Pregnancy: Which Test and Which Situation
Current Women`s Health Reviews Endoglin-Targeted Cancer Therapy
Current Drug Delivery Imaging Virus-Associated Cancer
Current Pharmaceutical Design Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
Current Drug Targets The Anti-Breast Cancer Effects of Green-Synthesized Zinc Oxide Nanoparticles Using Carob Extracts
Anti-Cancer Agents in Medicinal Chemistry Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension
Current Cancer Drug Targets Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design The Recent Development of Tetrahydro-Quinoline/Isoquinoline Based Compounds as Anticancer Agents
Current Topics in Medicinal Chemistry Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry Evolution and Pathogenesis of Oncoviruses Associated with Head and Neck Cancer: History and Current Concepts
Recent Patents on Biomarkers Synthesis of Silica Based Nanoparticles Against the Proliferation of Human Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Versatile Synthesis of Organic Compounds Derived from Ascorbic Acid
Current Organocatalysis Investigation of the Antiproliferative Action of the Quinoline Alkaloids Kokusaginine and Skimmianine on Human Cell Lines
Current Signal Transduction Therapy Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets